Allogeneic stem cell transplantation -using blood or marrow as the source -provides curative therapy for a substantial number of patients with hematological malignancies and immunodeficiency syndromes. This procedure is associated with substantial morbidity and mortality, even if performed using an HLA-matched sibling donor. In fact, during the first three decades of bone marrow transplantation more than 95% of allogeneic transplants were performed from sibling matched donors. Over the past decade the proliferation of transplant registries for matched unrelated donors as well as sensitive molecular methods of tissue typing have provided the opportunity for increasing use of alternative donors, mostly matched unrelated donors, using marrow or peripheral blood and also including stem cells obtained from umbilical cord or fetal liver. Improvements in the precision of HLA-typing methologies have resulted in identification of more closely matched donors, which in principle, will result in a lower incidence and severity of graft-versus-host disease (GVHD) and improved survival.
1,2 A few authors have reported that in some disease settings, such as chronic myeloid leukemia, unrelated donor transplant results approach those of sibling-matched allo-grafts. 3 However, this procedure has an even greater morbidity and mortality than transplants which utilize sibling matched donors. Furthermore, unrelated donor transplants are usually not available to the majority of patients who require this therapy urgently, due to the long time required to search for such a donor.
Another potential alternative donor is a genetically haploidentical family member. Such a donor is readily available in 90% of patients and over the past decade significant strides have been made in increasing the feasibility of such transplants by overcoming many of the historical barriers to this procedure. Due to the ease of donor accessibility in most instances, haploidentical transplants have been attempted over the past two decades. However, initial efforts were largely unsuccessful due to the overwhelming mortality associated with these procedures. The cardinal problems were those of intractable GVHD 4, 5 and graft rejection after transplants in which T cells were depleted from the donor cells. 6, 7 It soon became apparent that the standard conditioning regimen used at that time was not sufficiently immunosuppressive and failed to eradicate the cytotoxic T lymphocytes in the recipients, thus allowing graft rejection to occur unhindered (Table 1) . 6, 8, 9 A further major complication of haploidentical transplants has been the slow immune reconstitution that puts the patient at risk for severe morbidity and mortality for a Table 1 Major issues in haploidentical stem cell transplantation
Barriers to successful outcome Current or potential solutions
Graft failure Megadoses of CD34 donor cells 44, 46 Immunosuppressive conditioning regimen 41 Selective myeloablative conditioning regimen 32, 33 Intractable GVHD Maximal donor-cell immune suppression 41 T cell depletion [19] [20] [21] [22] Costimulatory blockade 18 Delayed immune reconstitution Cytokine manipulation 53 Adoptive cellular immunotherapy 56 Use of non-alloreactive CTL 24 ↓ GVL NK cell alloreactivity (KIR epitopemismatching) 64, 65 significantly longer period of time when compared to an HLA-matched sibling donor transplant. This effect remains even when adequate engraftment has occurred and GVHD is absent or well controlled, and often leads to viral, fungal or other opportunistic infections. [10] [11] [12] Although haploidentical transplantation has been sporadically performed over the past two decades it is only in the past few years that the emerging data suggest that such a procedure may have a role in patients other than those in desperate straits (Table 2) . A factor that has confounded interpretation of the data with haploidentical transplants has been the inherent advanced disease among recipients of this procedure. [13] [14] [15] [16] [17] [18] Inclusion of such a poor-risk patient population must be considered when interpreting the transplantrelated morbidity and mortality as well as the high rate of relapse.
Over the past decade major attempts have been made to successfully overcome, or ameliorate, some of these problems enabling haploidentical transplants to be conducted more safely and with more promising long-term efficacy (Table 1) . These directions will now be summarized.
Graft-versus-host disease (GVHD)
Historically, GVHD was one of the overwhelming problems associated with haploidentical transplantation making the danger of such a procedure almost prohibitive. In one of the largest early reports 4, 5 it was clearly shown that the risk of acute GVHD was significantly increased in patients receiving marrow grafts from donors incompatible from one, two, or three HLA loci. In fact, there was a direct relationship between the degree of HLA incompatibility and the risk for the development of acute GVHD. 2 As a group, patients receiving marrow grafts from HLA-incompatible donors had a relative risk for the reaction of 3.23 as compared with controls. The risk of severe acute GVHD was over 80% among patients who were incompatible for three HLA loci.
Methods to prevent the high rate of GVHD have relied upon altering the donor graft immunologic capabilities by removal of, or suppressing the function of all donor T cells regardless of their immunologic specificity. [19] [20] [21] [22] (Table 3 ). It is clear that the more profound the degree of T cell depletion the lower the risk for the development of acute GVHD. Infusion below a threshold of approximately 1-5 ϫ 10 4 CD3-positive cells per kg is usually sufficient to prevent the development of GVHD and can often enable such transplants to be performed without any GVHD prophylaxis. 23, 24 However, any relationship linking the degree of T cell depletion to the subsequent development of GVHD clearly is dependent on many other factors including the degree to which the patient has been previously treated and, most importantly, the level of immune suppression afforded by the conditioning regimen. Thus, the effects, positive and negative, of T cell depletion cannot be considered in isolation. 25 Recently, promising work in this area has demonstrated that inactivation of a select segment of the alloreactive T cell repertoire, through blockade of B7-mediated T cell costimulation, is possible and appears to result in a significant reduction in the risk of GVHD without an excessive risk for graft failure. Donor bone marrow may be treated ex vivo by co-culture with irradiated cells from the recipient in the presence of CTLA-4-Ig -an agent that inhibits B7:CD28-mediated co-stimulation -to induce anergy to alloantigens from the recipient with the subsequent relatively low risk of GVHD. [18] [19] [20] [21] [22] [23] [24] [25] [26] Preliminary clinical data using this novel approach have been encouraging, albeit in a small number of patients.
Other approaches to T cell depletion have included selective depletion of CD8 ϩ T lymphocytes by ex vivo treatment of the donor bone marrow with anti-Leu-2 monoclonal antibody and complement. 27 However, although this maneuver may abrogate the severity of GVHD, there are, as yet, no data in haploidentical transplantation that such manipulation, in itself, would reduce the risk of graft failure following T cell depletion.
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Graft failure
Strategies designed to reduce the risk for GVHD have not permitted the safe performance of haploidentical transplants. The cardinal problem lies in the fact that donor T cells facilitate engraftment, and assist in immunological reconstitution of the host. These actions prevent opportunistic infections, as well as contribute to the direct anti-tumor effect of the graft. Thus, T cell depletion of a graft prevents GVHD but theoretically exacts a prohibitive price. Historically, this effect was certainly true, but advances over the past 5 years have made major strides in this direction. It was originally believed that barriers to engraftment could be overcome by increasing the intensity of the conditioning regimen especially with higher doses of total body irradiation (TBI) and/or various combinations of high doses of myeloablative and immunosuppressive regimens. 16, [29] [30] [31] However, it soon became apparent that such intensive preparative regimens led to major organ toxicity in heavily pre-treated patients with advanced disease.
A decade ago it was demonstrated that graft failure also could be mediated by the competition of residual host hematopoietic progenitor cells which survive the conditioning together with the donor stem cells. 32, 33 Thus was born the concept of selective myeloablative therapy using drugs that are particularly potent stem cell toxins such as melphalan, 33 busulphan or thiotepa, 34 usually in combination with TBI. In general, TBI is an integral part of the conditioning regimen for haploidentical transplants, although, in patients who are unable to receive TBI, successful engraftment also can be established without this modality. 35 Although, his-671 Table 3 Methods of ex vivo T cell depletion of allogeneic donor grafts in clinical trials torically, TBI was given at higher total doses than when used for matched sibling donors, 15 more recent clinical results suggest that this maneuver may not be required. 17 Multiple other refinements to conventional conditioning regimens have been studied, all in an attempt to facilitate engraftment without excessive GVHD. Fludarabine is now commonly used in such conditioning regimens 17 and other immunosuppressive manipulations include high-dose methylprednisolone, 36 total nodal irradiation, 7 anti-T cell antibodies 37, 38 as well as increasing use of antithymocyte globulin (ATG). 17, 36, 39, 40 It is clear that one of the most difficult issues in the clinical performance of haploidentical transplantation has been the attempt to balance the necessary degree of myeloablation and immunosuppression with the resulting regimen-related toxicity. Attempts to ameliorate such toxicity have also focused on careful timing of sequential administration of myeloablative drugs and immunosuppressive therapy recognizing that procedural morbidity and mortality may be reduced if such toxic substances are not given simultaneously. Some successful experience has been published by the University of South Carolina. 41 With over 210 patients reported, the median time to engraftment was 16 days among patients in whom ATG was added to the TBIbased conditioning regimen. 41 
Bone Marrow Transplantation
Probably one of the most important developments in the increasing use of haploidentical transplantation has been reports from the University of Perugia, Italy, 17 of the successful use of a relatively nontoxic conditioning regimen using thiotepa, a single TBI dose of only 800 cGy, fludarabine and antithymocyte globulin. The 30-day treatmentrelated mortality from this conditioning regimen is about 10% and relies on fundamental work that established the concept that escalation of the stem cell dose directly contributed to the likelihood of the establishment of donor type chimerism. Cells within the CD34 ϩ compartment possess potent veto activity, which enable cells to neutralize cytotoxic T lymphocyte precursors (CTL-p) directed against veto cell antigens. The greater the number of CD34 stem cells, the greater the induction of tolerance. 42, 43 In humans, the concept of stem cell dose escalation was tested after technologies for the collection of peripheral blood progenitor cells became available following mobilization with cytokines. 44, 45 Megadoses of CD34 cells, eg, 10 ϫ 10 6 cells/kg, could be collected, T cell depleted, and infused and could successfully ensure engraftment, without the induction of excess GVHD. 46 This method has now become widely established and probably offers the greatest promise for current and future studies of haploidentical transplantation. 47 It appears that T cell-depleted allografts only have a limited capacity to reconstitute marrow mesenchymal cells. 48 Such mesenchymal cells not only contribute to the bone marrow microenvironment, but may also possess immunosuppressive properties. That could attenuate GVHD. 49 It may well be that, ideally, ex vivo generated mesenchymal cells, capable of long-term functional capacity, need to be administered as a supplement to T cell-depleted stem cell allografts to improve marrow stromal reconstitution. 48 
Delayed immune reconstitution
Having largely overcome the problems of engraftment and prevention of excessive GVHD, much of the focus for haploidentical transplants has centered on the marked delay in immune reconstitution in the months and years post transplant. The immune recovery after intensive T cell depletion that can now be achieved (infusing less than 5 ϫ 10 4 CD3 cells per kg) has been associated with a very high risk for post-transplant viral, fungal and other opportunistic infections. 10, 50, 51 The delay in immunologic reconstitution is the single most important cause of mortality in adults undergoing haploidentical bone marrow transplantation which may reach as high as 40% during the months and years post transplant. 17 Following absolute T cell depletion it may take anywhere from 6 to 18 months for the CD4 cells to recover.
The problem of delayed immunity is not merely due to the low number of T cells given with the graft. In adults, the decreased thymic function is of major importance. 52 Monocytes and dendritic cells, as well as other antigenpresenting cells, are also vital for the antigen-specific immunity. IL-12 is known to be a major cytokine in the initiation of protective Th 1 immunity against opportunistic infections and viruses. The observation that use of G-CSF post transplant to speed engraftment blocks IL-12 production by the antigen-presenting cells led to the discontinuation of the routine use of the cytokine post transplant. Preliminary clinical data indicate a more rapid rate of immune reconstitution, including the recovery of CD4 cells, at 3 months post transplant 53 with no adverse effect on the rate of engraftment. 42 A promising method for restoring specific immunity after transplants, albeit highly specialized and cumbersome, relies upon adoptive transfer of specific T cell clones. The potential and clinical use of this approach has been applied to many infections including candida, aspergillus and toxoplasma. 24, 54 The most extensive data have come from investigators at the Fred Hutchinson Cancer Research Center in Seattle, 55, 56 who developed a reliable method for the adoptive transfer of CMV-specific T cell clones. CMVspecific T cells are obtained from the haploidentical donor and the host T cells may be the target of alloreactivity. Donor T cells with specific reactivity for CMV antigens are cloned, a process which is time-consuming and also is technically complex. Infusion of such cells has resulted in very specific targeted immunity to CMV. Although not a routine laboratory procedure, the development of such adoptive therapy is clearly another promising clinical avenue to reduce the post-transplant toxicity from infection.
An approach, currently in the experimental design stage, involves the use of nonalloreactive T cells generated by purging IL-2 receptor (CD25) mixed lymphocyte response (MLR)-reactive T cells. 57 Promising clinical data have also been reported when anergy is induced after incubation with CTLA-4. 18, 58, 59 These methods for costimulatory blockade provide a theoretical means to induce tolerance and are likely to be more extensively studied over the next few years.
Nevertheless, some authors have urged caution with these approaches. Induction of tolerance might involve some risk for the development of severe GVHD by generating committed cytotoxic T lymphocytes (CTLs), should any of the CTL-p escape deletion or anergy induction. Once such anti-host CTLs are generated, it is very difficult to suppress their alloreactivity in vivo. 24 Another approach currently being evaluated is based on earlier studies which showed that CD8 ϩ CTL clones possess extremely high veto activity. 60 Preliminary data from the Weizmann Institute in Israel have focused on depleting such veto cells of alloreactive activity by generating non-alloreactive anti-third-party CTL clones. These cells are then evaluated by their capacity to facilitate engraftment of purified Sca-1 ϩ Lin Ϫ hematopoietic progenitors in sublethally irradiated mismatched recipients. 24, 47, [61] [62] [63] If successful, such an approach will drastically reduce the morbidity and mortality from impaired immunity post haploidentical transplantation and make this transplant approach more commonplace.
Impaired anti-tumor response
T cell depletion carries a high risk of leukemic relapse due mostly to abrogation of the graft-versus-leukemia effect. It thus seemed, at first, paradoxical that clinical reports of the most recent data in patients with advanced AML suggest a relatively low rate of relapse, especially in patients with acute myelogenous leukemia. 17 However, recent work has suggested that donor NK cell alloreactivity may play a significant role in graft-versus-leukemia effect. 64, 65 Donor NK cell alloreactivity probably is unique to mismatched transplants, as the donor NK cell killer inhibitory receptors (KIR) do not recognize the MHC allotypes of the recipient as 'self'. In this way these donor cells lyse the recipients' hematopoietic cells. Thus, NK cells originating post transplant from the donor stem cells do not exhibit tolerance towards the new host and a significant number of donortype NK cells clones are alloreactive against the recipient.
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Whether they exhibit such alloreactivity depends upon the recognition of a particular epitope shared by specific HLA allotypes.
In long-term follow-up of 75 high-risk AML patients the effect of this NK alloreactivity appeared to be impressive. Only one relapse occurred in 28 patients transplanted from donors with the potential to transfer anti-recipient NK alloreactivity. In contrast, 14 out of 47 patients relapsed when transplanted with grafts obtained from donors who could not transfer anti-recipient NK cell alloreactivity (P Ͻ 0.05). 66 Thus, these clinical data strongly support the hypothesis that only in mismatched transplants a graft-versus-leukemia effect, independent of T cell-mediated GVH reactions, controls leukemia relapse when KIR epitope incompatibility is in the GVHD direction. These authors therefore suggested that donor-versus-recipient NK cell alloreactivity may become a major criteria for donor selection in mismatched hematopoietic stem cell transplants.
Clinical perspective
While the performance of sibling-matched allogeneic transplantation has increased over the past four decades, it still can only be offered to the minority of patients who might benefit from such a transplant. The majority of individuals do not have an HLA-matched sibling donor and many are beyond the age where this can be performed reasonably safely.
For those subjects who lack an HLA-matched sibling donor, and are otherwise suitable candidates, a matched unrelated donor transplant is often performed. Although success rates are increasing [67] [68] [69] this procedure carries with it a high transplant-related mortality (30-40%) and a very high long-term morbidity. For advanced leukemia it is rarely successful, as many such patients do not survive the long waiting period (3-6 months) until a suitable donor can be found.
The largest recent update of matched unrelated transplants has come from the Fred Hutchinson Cancer Research Center in Seattle. These investigators reported that the longterm leukemia-free survival for the 81 patients with relapsed acute myelogenous leukemia was only 7%. 70 Furthermore, patient selection or 'survivability' greatly affects these results. A patient must survive the long waiting period to eventually allow a donor to be identified thereby excluding most of the patients. In fact, there has never been an intent-to-treat analysis of matched unrelated donor transplants for advanced acute myeloid leukemia (AML).
Haploidentical bone marrow transplantation offers a ready alternative to matched unrelated donor transplants. About 90% of patients have a suitable donor and the procedure can be offered within a very short period of time. The most recent experience published from the University of Perugia, Italy, suggests that associated morbidity and mortality do not exceed that reported for matched unrelated donor transplants; most importantly, in AML, there is not an excessive risk of relapse. 17, 47 A further update 71 on 111 patients with acute leukemia is shown in Figure 1 . The 5- Bone Marrow Transplantation year event-free survival for patients with refractory disease was a disappointing 15%. Such data, however, included all patients -including those who would never have survived long enough to wait for an unrelated donor to be found. In contrast, for 27 patients with very high risk features in first or second complete remission the 5-year event-free survival was 45% with a relapse rate of less than 15% (Figure 2 ). This same Perugia group has strongly recommended, with supporting data of reduced transplant-related mortality, the use of the CliniMACS (Miltenyi Biotech, Bergisch Gladbach, Germany) for positive CD34 cell selection. In sequential studies, using different stem cell columns for CD34 ϩ selection, the transplant-related mortality was 63% using the Isolex (Baxter, Deerfield, IL, USA), 42% with the Ceprate (CellPro, Bothell, WA, USA) vs only 20% with the CliniMACS. 72 Although these are not prospective comparisons, and greater patient numbers are required, these data cautiously support the preferential use of the CliniMACS. With small patient numbers, other groups are reporting similar data, using the same approach as the Perugia group. 73 However, another report with few patients using this approach -but with the Isolex columns -was less enthusiastic. 74 Other groups are reporting on different technologies, such as the blockade of B7-mediated T cell costimulation, 18 and others have not yet reported their experience although this form of transplantation is being increasingly performed.
Conclusion
Haploidentical bone marrow transplantation clearly is a viable option for those patients who do not have an HLAcompatible sibling donor. Almost all patients have a genetically haploidentical family member and the procedure can be performed without delay. Although the clinical experience is limited, recent data are encouraging and suggest that this procedure is an acceptable alternative to matched unrelated donor transplantation and, in certain circumstances, may be the preferred option. Much progress has been made in the control of GVHD without increasing the rate of non-engraftment. The most encouraging data, reporting on a rapid rate of engraftment, have followed the use of 'mega doses' of stem cells obtained from the donor peripheral blood. Of particular note, it appears that in some T cell-depleted haploidentical transplants, an NK-mediated graft-versus-leukemia effect may be in place, leading to a reportedly low rate of relapse. Post-transplant infectious complications remain the single most important barrier yet to be overcome. New directions in the use of adoptive cellular immunity appear to be most promising, although such a procedure remains highly specialized. Preclinical data demonstrating that anti-thirdparty non-alloreactive cytotoxic T lymphocytes may improve immunologic reconstitution in dramatic fashion, have yet to be successfully reported in humans.
The use of prospective, multi-center, controlled clinical trials and companion translational studies will further improve upon this modality.
